GSK response to news article in The Guardian on UK legal proceedings related to Avandia
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/stories/logo/gsk.gif)
Bristol-Myers Squibb reports fourth quarter financial results
- Details
- Category: Bristol-Myers Squibb
![Bristol-Myers Squibb Bristol-Myers Squibb](/images/stories/logo/bms.gif)
Amgen's full year 2012 revenues increased 11 percent to $17.3 billion
- Details
- Category: Amgen
![Amgen Amgen](/images/stories/logo/amgen.gif)
Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
- Details
- Category: Novartis
![Novartis Novartis](/images/stories/logo/novartis_b.gif)
Takeda establishes new trading company and reinforces business structure in China
- Details
- Category: Takeda
![Takeda Takeda](/images/stories/logo/takeda.gif)
Novartis makes progress in the fight to eliminate leprosy worldwide
- Details
- Category: Novartis
![Novartis Novartis](/images/stories/logo/novartis_b.gif)
FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](/images/stories/logo/boehringeringelheim.gif)
More Pharma News ...
- Sanofi updates its Research & Development pipeline
- Phase III data show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC
- Bayer receives approval for new long-term contraceptive Skyla™ in the U.S.
- Abbott initiates clinical trial of Absorb TM in the United States
- Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
- Abbott completes separation of research-based pharmaceuticals business
- FDA approves ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation